Rosenberg Anthony Stock Option Grant

Anthony Rosenberg, a director at Cullinan Therapeutics, Inc., was granted a stock option on June 16, 2026, for 25,319 shares of Common Stock. The option has an exercise price of $13.55 per share. The option will vest in full on the earlier of June 16, 2027, or the date of the Issuer's next annual meeting, contingent upon Rosenberg's continued service as a director. This transaction, categorized as an officer/director change due to its nature, is reported on Form 4.